Search clinical trials for: Zolendronic Acid

Total 23859 results

Southwest Oncology Group
National Cancer Institute (NCI)

Withdrawn

S0308 Zoledronate or Ibandronate in Preventing Bone Problems in Women With Stage IV Breast Cancer That Has Spread to the Bone

Pain | Breast Cancer | Metastatic Cancer | Hypercalcemia of Malignancy
Hebei Tumor Hospital

Unknown

Pilot Study of Zoledronic Acid in Combination With First-line Chemotherapy in Aged Patients With Lung Cancer

Lung Cancer

China
Ottawa Hospital Research Institute
Canadian Breast Cancer Foundation

Completed

The ODYSSEY TRIAL Phase IV Trial Evaluating the Palliative Benefit of Pamidronate or Zoledronic Acid in Breast Cancer (ER11-03)

Breast Cancer

Canada
Chugai Pharmaceutical
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases

Pain | Breast Cancer | Metastatic Cancer | Hypercalcemia of Malignancy

United States
424 General Military Hospital
Leiden University Medical Center; 251 Hellenic Air Force & VA General Hospital

Completed

Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation (AfterDmab)

Postmenopausal Osteoporosis

Greece
University of Southern California
National Cancer Institute (NCI)

Withdrawn

Genetics in Predicting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid

Malignant Neoplasm | Musculoskeletal Complications

United States
Novartis Pharmaceuticals

Completed

Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer

Breast Cancer

United States
Ondokuz Mayıs University

Completed

Changes of GCF Levels of RANKL and Osteoprotegerin in Postmenopausal Osteoporosis

Chronic Periodontitis
Shenzhen People's Hospital

Recruiting

Denosumab vs Zoledronate After Lumbar Fusion

Osteopenia | Lumbar Spondylolisthesis

China
Novartis Pharmaceuticals

Completed

Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period

Paget's Disease of Bone

United States, Germany, Spain, United Kingdom, Canada, France, Belgium, South Africa, Australia, New Zealand
City of Hope Medical Center
National Cancer Institute (NCI)

Terminated

Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid

Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-positive Breast Cancer | Invasive Ductal Breast Carcinoma

United States
Nantes University Hospital

Terminated

Study of the Effect of Zoledronate on Local Recurrence After Surgical Treatment of Giant Cell Tumors of Bone Zométa (Zometa)

Giant Cell Tumors of Bone

France
Susan L. Greenspan

Recruiting

Preserving Geriatric Muscle With an Osteoporosis Medication

Osteoporosis

United States
Ultragenyx Pharmaceutical Inc
Mereo BioPharma

Completed

A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804 (Asteroid)

Osteogenesis Imperfecta Type III | Osteogenesis Imperfecta Type IV | Osteogenesis Imperfecta, Type I

United States, Canada, Denmark, France, United Kingdom
Shenzhen People's Hospital

Completed

Denosumab vs Zoledronate After Vertebroplasty

Denosumab Allergy | Zoledronic Acid Allergy

China
Amgen

Completed

Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis

Post Menopausal Osteoporosis

Canada, Denmark, United States, Belgium, Poland, Spain, Australia
Hamad Medical Corporation

Terminated

Denosumab Versus Zoledronic Acid in Thalassemia-Induced Osteoporosis (DOHA)

Osteoporosis | Thalassemia Majors (Beta-Thalassemia Major)

Qatar
National Cancer Institute (NCI)

Completed

Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Novartis Pharmaceuticals

Terminated

Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I

Multiple Myeloma Stage I

Germany
Novartis Pharmaceuticals

Terminated

Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow (MRD-1)

Primary Breast Cancer

Germany
424 General Military Hospital

Recruiting

Sequential Therapies After Osteoanabolic Treatment (START)

Osteoporosis, Postmenopausal

Greece, Germany, Italy
University of Aarhus

Terminated

The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta

Osteogenesis Imperfecta

Denmark
Fudan University

Unknown

Clinical Study of Sorafenib and Zoledronic Acid to Treat Advanced HCC

Hepatocellular Carcinoma

China
Hospital Authority, Hong Kong
Baxter Healthcare Corporation

Completed

Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

Prostatic Neoplasms | Bone Density

China
Massachusetts General Hospital

Completed

Denosumab and Teriparatide Study (DATA-HD and DATA-EX) (DATA-HD)

Postmenopausal Osteoporosis

United States
Translational Research Center for Medical Innovation...
Kyoto University, Graduate School of Medicine

Completed

Androgen Blockade Therapy With or Without Zoledronic Acid in Treating Patients With Prostate Cancer and Bone Metastases (ZAPCA)

Prostate Cancer | Metastatic Cancer

Japan
Mayo Clinic
National Cancer Institute (NCI)

Completed

Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain

Pain | Multiple Myeloma and Plasma Cell Neoplasm

United States
Susan L. Greenspan
National Institutes of Health (NIH); National Institute on Aging (NIA)

Completed

Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II) (ZEST II)

Osteoporosis, Postmenopausal | Osteoporotic Fractures

United States
Washington University School of Medicine
United States Department of Defense; Aclaris Therapeutics, Inc.

Not yet recruiting

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer

Breast Cancer | Osteoporosis

United States
National Cancer Institute, Naples

Completed

ZANTE: Zometa and Taxotere in Hormone Refractory Prostate Cancer (ZANTE)

Metastatic Prostate Cancer

Italy
Novartis

Completed

Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis

Osteoporosis

United States, Belgium, Germany, Spain
Novartis Pharmaceuticals

Completed

Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast®

Hypocalcemia | Paget's Disease of the Bone

United States
Institut Cancerologie de l'Ouest

Recruiting

Multicentre Medical-economic Study Evaluating the Efficacy of Adding ZOlédronique Acid to STERéotaxique Radiotherapy in the Treatment of Vertebral Metastases (ZOSTER)

Vertebral Metastasis

France
Northwestern University
Novartis

Terminated

Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation

Prostate Cancer | Osteoporosis

United States
University of Wisconsin, Madison
Novartis

Terminated

Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer

Kidney Cancer

United States
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy

Prostate Cancer | Osteoporosis

United States, Canada
Novartis Pharmaceuticals

Completed

Non-small Cell Lung Cancer Study US75 (Z-PACT) (ZPACT)

Non Small Cell Lung Carcinoma

United States
Massachusetts General Hospital
Dana-Farber Cancer Institute; Brigham and Women's Hospital; Abbott

Completed

Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone

Prostate Cancer | Adenocarcinoma of the Prostate

United States
Central Hospital, Nancy, France

Completed

Efficacy of Zoledronic Acid in Osteoporosis of Children With Multiple Disabilities (ZOMETA)

Multiple Disability | Osteoporosis

France
Novartis Pharmaceuticals

Completed

Bisphosphonate Treatment of Osteogenesis Imperfecta

Osteogenesis Imperfecta

United States
Assiut University

Unknown

Diagnosis of Osteogenesis Imperfecta in Children

Bone Disease, Metabolic

Egypt
Hoosier Cancer Research Network
Novartis Pharmaceuticals; Walther Cancer Institute

Terminated

Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple Myeloma

Multiple Myeloma

United States
Tokyo Women's Medical University

Completed

Adoptive Immunotherapy, Aldesleukin, and Zoledronate in Treating Patients With Stage IV Kidney Cancer and Lung Metastases

Kidney Cancer | Metastatic Cancer

Japan
Hoffmann-La Roche
Roche Pharma AG

Terminated

Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma (COMPARE)

Multiple Myeloma

Germany
Novartis Pharmaceuticals

Completed

Zoledronic Acid in Children (1 -17 Years) With Severe Osteogenesis Imperfecta

Osteogenesis Imperfecta

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Zoledronic Acid for the Treatment of Osteoporosis in Men

Osteoporosis

United States, Canada, Australia
Susan L. Greenspan
National Institutes of Health (NIH); National Institute on Aging (NIA)

Recruiting

Romosozumab Use to Build Skeletal Integrity (RUBI)

Osteoporosis | Osteoporosis, Postmenopausal | Osteoporosis Fracture

United States
Aarhus University Hospital
University of Aarhus; Amgen

Completed

Treatment With Zoledronic Acid Subsequent to Denosumab in Osteoporosis (ZOLARMAB)

Osteoporosis

Denmark
Novartis Pharmaceuticals

Completed

Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older

Osteopenia

United States

Search clinical trials for: Zolendronic Acid

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations